Table 2.

Genotypic resistance surveillance^a

Parameter	No. (%) of patients with indicated value(s)/total no. of patients
	Baseline			Wk 52			Wk 104
	LA-EA	EA-EA	P	LA-EA	EA-EA	P	LA-EA	EA-EA	P
Patients with HBV mutants resistant to ADV or ETV	12 (26.7)	8 (17.8)	0.31	15 (33.3)	3 (6.7)	<0.01	6 (13.3)	2 (4.4)	0.27
Patients with retainment of indicated baseline HBV mutant(s)	12	8	0.31	10/12 (83.3)	3/8 (37.5)	0.06	6/12 (50)	2/8 (25)	0.37
rtA181T,V + rtN236T	3	0		3	0		3	0
rtA181T + rtN236T	3	1		3	0		1	0
rtA181V + rtN236T	0	3		0	1		0	1
rtA181T	4	1		2	0		0	0
rtA181V	2	1		2	0		2	0
rtT184A	0	1		0	1		0	0
rtA181T + rtN236T + rtM250L	0	1		0	1 [rtM250L]		0	1 [rtM250L]
Patients with additional emergence of indicated HBV mutant(s)	NA	NA	NA	5/33 (15.2)	0/38 (0)	0.02	0/33	0/38	NA
rtA181T + rtN236T	NA	NA		1	0		0	0
rtA181V + rtN236T	NA	NA		2	0		0	0
rtA181T	NA	NA		1	0		0	0
rtN236T	NA	NA		1	0		0	0

^aBaseline, week 0 in the original 52-week study (18). NA, not applicable.